Stock Price and Market Movement
On 14 Jan 2026, Kronox Lab Sciences Ltd recorded a day decline of 0.57%, underperforming the Sensex which fell by 0.20% on the same day. The stock’s downward trend extends beyond daily fluctuations, with a one-week loss of 5.67% compared to the Sensex’s 1.76% drop. Over the past month, the stock has declined by 6.38%, significantly lagging the Sensex’s 2.12% fall. The three-month performance is particularly notable, with Kronox Lab Sciences Ltd falling 9.75% while the Sensex gained 1.75% in the same period.
Year-to-date, the stock has lost 5.50%, again underperforming the Sensex’s 2.06% decline. The one-year performance is more stark, with a 26.55% loss compared to the Sensex’s 9.10% gain. Over three and five years, the stock has shown no appreciable growth, remaining flat, while the Sensex has delivered returns of 38.50% and 68.32% respectively. The ten-year comparison further highlights the stock’s stagnation, with zero growth against the Sensex’s 236.91% rise.
Technical Indicators and Valuation Metrics
Kronox Lab Sciences Ltd is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent bearish momentum. The stock’s valuation remains elevated despite the price decline, with a Price to Book Value ratio of 5.4, indicating a very expensive valuation relative to its book value. The company’s Return on Equity (ROE) stands at 28.6%, a figure that suggests strong profitability but contrasts with the stock’s poor market performance.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Financial Performance and Growth Trends
Over the last five years, Kronox Lab Sciences Ltd has recorded a modest net sales compound annual growth rate (CAGR) of 6.80%, reflecting limited expansion in its core business. The company’s results for the quarter ended September 2025 were flat, indicating a lack of momentum in recent earnings. Despite the subdued sales growth, profits have increased by 19% over the past year, a divergence that may be attributed to cost management or other factors not detailed here.
However, this profit growth has not translated into positive stock returns, as the share price has declined by 26.55% over the same period. The stock’s performance has also lagged the broader BSE500 index over one year, three months, and three years, highlighting its relative underperformance within the market.
Ownership and Capital Structure
The company maintains a low average debt-to-equity ratio of zero, indicating a debt-free or minimal debt capital structure. Majority ownership rests with promoters, suggesting concentrated control over corporate decisions. The market capitalisation grade assigned to Kronox Lab Sciences Ltd is 4, reflecting its micro-cap status within the Specialty Chemicals sector.
Considering Kronox Lab Sciences Ltd? Wait! SwitchER has found potentially better options in Specialty Chemicals and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Specialty Chemicals + beyond scope
- - Top-rated alternatives ready
Mojo Score and Rating Changes
Kronox Lab Sciences Ltd currently holds a Mojo Score of 30.0, categorised as a Sell grade. This rating was downgraded from Hold on 7 Oct 2025, reflecting a reassessment of the company’s prospects and market standing. The downgrade aligns with the stock’s ongoing price weakness and underwhelming financial metrics.
The company operates within the Specialty Chemicals industry and sector, a space that has seen varied performance across peers. Kronox Lab Sciences Ltd’s relative underperformance against sector benchmarks and the broader market indices underscores the challenges it faces in delivering shareholder value.
Summary of Market Context
The stock’s proximity to its 52-week low, combined with its sustained underperformance across multiple time frames, paints a picture of a company struggling to gain market traction. Despite a strong ROE and profit growth, the valuation remains elevated, and the share price has not reflected these fundamentals positively. The absence of debt provides financial stability, but this has not translated into improved market sentiment or price appreciation.
Overall, Kronox Lab Sciences Ltd’s stock performance highlights a significant divergence between accounting profitability and market valuation, with the share price reaching historic lows amid a challenging market environment.
Unlock special upgrade rates for a limited period. Start Saving Now →
